Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelika Batorova

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Opinion in Hematology|August 5, 2006
Continuous infusion of coagulation factors: current opinionAngelika Batorova, Uri Martinowitz
Thrombosis Research|January 12, 2011
Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patientsAnna Klukowska, Jerzy Windyga, Angelika Batorova
Haematologica|March 4, 2008
Evaluation of factor V mRNA to define the residual factor V expression levels in severe factor V deficiencyBarbara Lunghi, Mirko Pinotti, Iva Maestri, et al.
Seminars in Thrombosis and Hemostasis|September 12, 2013
Challenges in the management of hemophilia B with inhibitorAngelika Batorova, Anna Morongova, Giuseppe Tagariello, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 26, 2012
Rare bleeding disordersFlora Peyvandi, Paula H B Bolton-Maggs, Angelika Batorova, et al.
Cardiovascular Toxicology|October 8, 2014
Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation?Lubica Roziakova, Martin Mistrik, Angelika Batorova, et al.
Patient Preference and Adherence|May 6, 2021
A Cross-National Survey of People Living with Hemophilia: Impact on Daily Living and Patient Education in Central EuropeAtanas Banchev, Angelika Batorova, Barbara Faganel Kotnik, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 23, 2016
Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge TestJan Jacques Michiels, Petr Smejkal, Miroslav Penka, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 17, 2021
Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?Katharina Holstein, Sandra Le Quellec, Robert Klamroth, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 19, 2022
Are all licensed haemostatic agents for haemophilia therapy accessible to patients?Karin Berger, Angelika Batorova, Rhonda Bohn, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Opinion in Hematology|August 5, 2006
Continuous infusion of coagulation factors: current opinionAngelika Batorova, Uri Martinowitz
Thrombosis Research|January 12, 2011
Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patientsAnna Klukowska, Jerzy Windyga, Angelika Batorova
Haematologica|March 4, 2008
Evaluation of factor V mRNA to define the residual factor V expression levels in severe factor V deficiencyBarbara Lunghi, Mirko Pinotti, Iva Maestri, et al.
Seminars in Thrombosis and Hemostasis|September 12, 2013
Challenges in the management of hemophilia B with inhibitorAngelika Batorova, Anna Morongova, Giuseppe Tagariello, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 26, 2012
Rare bleeding disordersFlora Peyvandi, Paula H B Bolton-Maggs, Angelika Batorova, et al.
Cardiovascular Toxicology|October 8, 2014
Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation?Lubica Roziakova, Martin Mistrik, Angelika Batorova, et al.
Patient Preference and Adherence|May 6, 2021
A Cross-National Survey of People Living with Hemophilia: Impact on Daily Living and Patient Education in Central EuropeAtanas Banchev, Angelika Batorova, Barbara Faganel Kotnik, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 23, 2016
Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge TestJan Jacques Michiels, Petr Smejkal, Miroslav Penka, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 17, 2021
Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?Katharina Holstein, Sandra Le Quellec, Robert Klamroth, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 19, 2022
Are all licensed haemostatic agents for haemophilia therapy accessible to patients?Karin Berger, Angelika Batorova, Rhonda Bohn, et al.
Pageof 3